Lindsey Shapiro, PhD,  science writer—

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Lung transplants for CF on decline since Trikafta: U.S. study

Lung transplant rates among people with cystic fibrosis (CF) in the U.S. have declined dramatically since the approval of Trikafta (elexacaftor/tezacaftor/ivacaftor), a study found. However, almost half of patients who received transplants in recent years were on Trikafta before their procedures. Moreover, a notable proportion of CF patients…

Type 2 inflammation in CF linked to worse lung function

Nearly two-thirds of cystic fibrosis (CF) patients in a study showed signs of type 2 inflammation, which was associated with worse lung function, more infections, and a higher risk of death. This form of inflammation, most commonly linked to allergic conditions, was reduced somewhat after treatment with CFTR…

Gene editing targeting lungs shows promise in preclinical study

A lung-targeted gene-editing therapy designed using technology from ReCode Therapeutics was able to successfully correct a disease-causing CFTR gene mutation in lung cells derived from cystic fibrosis (CF) patients, according to a recent proof-of-concept study. The therapy, developed using ReCode’s Selective Organ Targeting (SORT) lipid nanoparticles (LNPs), was…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.